Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
JNCI Journal of the National Cancer Institute2017Vol. 109(12)
Citations Over TimeTop 1% of 2017 papers
Alexander W. Wyatt, Matti Annala, Rahul Aggarwal, Kevin Beja, Felix Y. Feng, Jack Youngren, Adam Foye, Paul Lloyd, Matti Nykter, Tomasz M. Beer, Joshi J. Alumkal, George Thomas, Robert E. Reiter, Matthew B. Rettig, Christopher P. Evans, Allen C. Gao, Kim N., Eric J. Small, Martin Gleave
Abstract
Our study shows that, in the majority of patients, a ctDNA assay is sufficient to identify all driver DNA alterations present in matched metastatic tissue and supports development of DNA biomarkers to guide mCRPC patient management based on ctDNA alone.
Related Papers
- Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.(2017)
- → Urinary Cell-Free DNA in Liquid Biopsy and Cancer Management(2022)41 cited
- → Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy(2022)39 cited
- → ‘Longing’ for the Next Generation of Liquid Biopsy: The Diagnostic Potential of Long Cell-Free DNA in Oncology and Prenatal Testing(2023)16 cited
- → Challenges in the implementation of ultrasensitive liquid biopsy approaches in precision oncology(2023)14 cited